Table of Contents
Advances in Hepatology
Volume 2014 (2014), Article ID 357287, 15 pages
http://dx.doi.org/10.1155/2014/357287
Review Article

Noninvasive Biomarkers of Liver Fibrosis: An Overview

Fellowship of American College of Physicians (FACP) and Arab Board and Saudi Board of Internal Medicine, Medical Department, King AbdulAziz University Hospital, P.O. Box 80215, Jeddah 21589, Saudi Arabia

Received 14 October 2013; Revised 11 January 2014; Accepted 27 February 2014; Published 15 April 2014

Academic Editor: Ned Snyder

Copyright © 2014 Hind I. Fallatah. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Chronic liver diseases of differing etiologies are among the leading causes of mortality and morbidity worldwide. Establishing accurate staging of liver disease is very important for enabling both therapeutic decisions and prognostic evaluations. A liver biopsy is considered the gold standard for assessing the stage of hepatic fibrosis, but it has many limitations. During the last decade, several noninvasive markers for assessing the stage of hepatic fibrosis have been developed. Some have been well validated and are comparable to liver biopsy. This paper will focus on the various noninvasive biochemical markers used to stage liver fibrosis.